Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Financial Officer | April 30, 2019 | June 07, 2019 |
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director | November 18, 2020 | November 19, 2020 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | May 29, 2025 | June 02, 2025 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director | May 21, 2026 | May 26, 2026 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date April 30, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,686 |
Reported balance
After 2019-04-30 transaction · row 1
1 source rowRow 1 · 2019-04-30 · Grant · Acquired 176 · Balance 47,686 F1: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan.
Jiya Acquisition Corp.
Report date November 18, 2020 · Filed November 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person holds 30,000 shares of Class B Common Stock of the Issuer ("Class B Shares"). The Class B Shares will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: The Class B Shares held by the Reporting Person are subject to forfeiture if the Reporting Person is removed from office as a director or voluntarily resigns from the Reporting Person's position with the Issuer at any time before the consummation of the Issuer's initial business combination.
Kyverna Therapeutics, Inc.
Report date May 29, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,634 |
Reported balance
After 2025-05-29 transaction · row 1
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 16,634 · Balance 16,634 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2035-05-29 | Direct | 65,351 |
Reported balance
After 2025-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-29 · Grant · Acquired 65,351 · Balance 65,351 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
vTv Therapeutics Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.08 · Expires 2036-06-26 | Direct | 16,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 6,000 · Balance 16,000 F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cascadian Therapeutics, Inc.
Report date March 09, 2018 · Filed March 13, 2018
Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 1
1 source rowRow 1 · 2018-03-09 · Other · Disposed 21,006 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-09 · Disposition to issuer · Disposed 13,927 · Balance 0 F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
F2: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F3: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.
F4: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
MYRIAD GENETICS INC
Report date June 06, 2024 · Filed June 07, 2024
Section 16 reporting ended · disclosed 2024-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,917 |
Reported balance
Holding disclosure · report date 2024-06-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 32,917 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 20:10 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 6,000 | $35.08 Strike: $35.08 | $210,480.00 |
DisclosureSEC source: 0001238403-26-000006 · wk-form4_1782763816.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Class A Common Stock · 6,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:31 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0001238403-26-000004 · form4-06102026_080629.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-06-07 F1 · derivative.exercise_date: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001238403-26-000002 · form4-05262026_040510.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400 | Not disclosed Strike: $169.50 | Not disclosed |
DisclosureSEC source: 0001238403-25-000007 · form4-12152025_111257.xml · derivative · entry 6 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400 shares Expires 2033-05-24 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 400 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001238403-25-000007 · form4-12152025_111257.xml · derivative · entry 5 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock · 400 shares Expires 2033-05-24 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (right to buy) · Derivative | 88 | Not disclosed Strike: $1,143.00 | Not disclosed |
DisclosureSEC source: 0001238403-25-000007 · form4-12152025_111257.xml · derivative · entry 4 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88 shares Expires 2031-05-19 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (right to buy) · Derivative | 88 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001238403-25-000007 · form4-12152025_111257.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88 Underlying: Common Stock · 88 shares Expires 2031-05-19 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 458 | Not disclosed Strike: $564.00 | Not disclosed |
DisclosureSEC source: 0001238403-25-000007 · form4-12152025_111257.xml · derivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458 shares Expires 2030-09-08 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 458 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001238403-25-000007 · form4-12152025_111257.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458 Underlying: Common Stock · 458 shares Expires 2030-09-08 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:21 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.67 | $0.00 |
DisclosureSEC source: 0001238403-25-000005 · form4-09242025_080900.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 23:38 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001415889-25-020270 · form4-07242025_110741.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-07-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 4,000 | $16.59 Strike: $16.59 | $66,360.00 |
DisclosureSEC source: 0001641489-25-000046 · wk-form4_1749760089.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 4,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 65,351 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000950170-25-080456 · ownership.xml · derivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,351 Underlying: Common Stock · 65,351 shares Expires 2035-05-29 F2 · derivative.exercise_date: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:35 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 16,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080456 · ownership.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,634 F1 · shares: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:40 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 6,000 | $17.22 Strike: $17.22 | $103,320.00 |
DisclosureSEC source: 0001641489-24-000051 · wk-form4_1719520815.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Class A Common Stock · 6,000 shares Expires 2034-06-25 F1 · derivative.exercise_date: The options will vest monthly over the three year period following date of grant. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 21:57 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,788 | $22.05 | $83,525.40 |
DisclosureSEC source: 0001238403-24-000002 · wk-form4_1717538237.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,917 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 21:57 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,788 | $22.04 | $83,487.52 |
DisclosureSEC source: 0001238403-24-000002 · wk-form4_1717538237.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,705 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-014493 · form4-05242024_080517.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 22:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 8,638 | $23.01 | $198,760.38 |
DisclosureSEC source: 0001238403-23-000002 · wk-form4_1685744119.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,493 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001238403-23-000002 · wk-form4_1685744119.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,131 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:40 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-032663 · doc4.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 06, 2022 Filed Jun 6, 2022 23:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 6,424 | $19.25 | $123,672.92 |
DisclosureSEC source: 0001238403-22-000002 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,980 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.57, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 17,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016223 · wf-form4_165429164220216.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,404 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:12 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-22-032503 · doc4.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:41 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,139 | $30.52 | $95,794.75 |
DisclosureSEC source: 0001238403-21-000008 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,129 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $30.65, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 12,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001238403-21-000006 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,268 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 23:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 7,142 | $28.99 | $207,023.01 |
DisclosureSEC source: 0001238403-21-000004 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,420 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $29.30, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2021 Filed May 28, 2021 22:48 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 15,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001238403-21-000002 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,562 F1 · kind: On May 27, 2021, the Company rescinded Mr. Spiegelman's grant of 15,889 restricted stock units granted on December 4, 2020 and reported on the Form 4 filed with the Securities and Exchange Commission on December 7, 2020. Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $15.24 | $0.00 |
DisclosureSEC source: 0001209191-21-035152 · doc4.xml · derivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 22:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001238403-20-000007 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,451 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| May 27, 2020 Filed May 28, 2020 15:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 20,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001238403-20-000005 · edgardoc.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,562 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| April 30, 2019 Filed Jun 7, 2019 22:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 176 | $68.78 | $12,105.63 |
DisclosureSEC source: 0001567619-19-013093 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,686 F1 · date: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 17:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 13,473 | $89.00 | $1,199,097.00 |
DisclosureSEC source: 0001567619-19-008275 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,510 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 26, 2019. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 100 | $90.00 | $9,000.00 |
DisclosureSEC source: 0001567619-19-007872 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,983 F1 · date: Trade made pursuant to a 10b5-1 plan executed on February 26, 2019. Read SEC document |
| March 22, 2019 Filed Mar 27, 2019 00:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,598 | $88.05 | $316,803.90 |
DisclosureSEC source: 0001567619-19-007684 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,083 Read SEC document |
| March 15, 2019 Filed Mar 20, 2019 00:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 23,450 | $0.00 Strike: $94.53 | $0.00 |
DisclosureSEC source: 0001567619-19-007257 · doc1.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 Underlying: Common Stock · 23,450 shares Expires 2029-03-14 F2 · date: Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2019 Filed Mar 20, 2019 00:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007257 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,681 F1 · price: Restricted stock units granted on March 15, 2019. Price not applicable. Read SEC document |
| March 15, 2019 Filed Mar 20, 2019 00:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,227 | $94.53 | $683,168.31 |
DisclosureSEC source: 0001567619-19-007257 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,311 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 01:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 912 | $94.76 | $86,421.12 |
DisclosureSEC source: 0001567619-19-006240 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,538 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 01:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-006240 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,450 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| October 31, 2018 Filed Dec 20, 2018 23:06 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 175 | $68.78 | $12,036.85 |
DisclosureSEC source: 0001567619-18-008459 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,245 F1 · date: Represents shares acquired by the reporting person on October 31, 2018, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 472 | $99.01 | $46,732.72 |
DisclosureSEC source: 0001140361-18-030011 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,070 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 15, 2017. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 9,528 | $99.00 | $943,272.00 |
DisclosureSEC source: 0001140361-18-030011 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,542 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 15, 2017. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,711 | $92.07 | $157,531.77 |
DisclosureSEC source: 0001140361-18-027605 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,070 Read SEC document |
| April 30, 2018 Filed Jun 7, 2018 00:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 167 | $68.78 | $11,486.59 |
DisclosureSEC source: 0001140361-18-027605 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,781 F1 · date: Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan. F2 · balance_after: Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 86 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 15 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018. Read SEC document |
| April 23, 2018 Filed Apr 26, 2018 00:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 11,059 | $82.15 | $908,496.85 |
DisclosureSEC source: 0001140361-18-019613 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,543 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 11, 2017. Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 00:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,583 | $81.36 | $291,512.88 |
DisclosureSEC source: 0001140361-18-015081 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,602 Read SEC document |
| March 22, 2018 Filed Apr 27, 2018 23:32 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,598 | $81.36 | $292,733.28 |
DisclosureSEC source: 0001140361-18-020306 · doc1.xml · nonDerivative · entry 1 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,587 F1 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 39,900 | $0.00 Strike: $83.57 | $0.00 |
DisclosureSEC source: 0001140361-18-014184 · doc1.xml · derivative · entry 3 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 Underlying: Common Stock · 39,900 shares Expires 2028-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-014184 · doc1.xml · nonDerivative · entry 2 SPIEGELMAN DANIEL K · CIK 0001238403 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,185 F1 · price: Restricted stock units granted on March 15, 2018. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.